Key Highlights

  • The FDA's formal decision deadline, known as the PDUFA date, for Biofrontera's application covering Ameluz photodynamic therapy in superficial basal cell carcinoma was set for September 28, 2026.
  • The agency actually approved the application on September 14, roughly two weeks ahead of that deadline, after pivotal trial data showed a 65.5% lesion clearance rate versus 4.8% for placebo.
  • Biofrontera plans a commercial launch of Ameluz PDT in the new skin cancer indication in the first quarter of 2027, pending Manufacturing readiness and lamp Supply logistics.
  • The company has separately disclosed going-concern language and an unresolved International Trade Commission dispute tied to importing its BF-RhodoLED lamp series, tempering enthusiasm around the approval.

A Decision That Arrived Before the Deadline

Biofrontera's supplemental new drug application covering Ameluz photodynamic therapy for superficial basal cell carcinoma carried a PDUFA target date of September 28, 2026, the formal deadline by which the FDA had committed to rendering a decision. In practice, the agency moved faster than that deadline required, approving the application on September 14, a full two weeks ahead of schedule. That approval rested on pivotal trial results showing a 65.5% target lesion clearance rate among patients treated with Ameluz PDT, compared with just 4.8% in the placebo arm, a gap wide enough to support approval without requiring an advisory committee review. An early approval of this kind typically signals that the agency found the clinical data straightforward to evaluate, without significant safety or manufacturing questions requiring the full review window.

What Ameluz PDT Approval Means for Biofrontera's Business

Ameluz PDT already carries FDA approval for actinic keratosis, a common precancerous skin condition, and this new clearance extends its use to superficial basal cell carcinoma, one of the most frequently diagnosed forms of skin cancer. That expansion meaningfully broadens Biofrontera's addressable patient population, offering a non-invasive, light-activated alternative to surgical removal or Mohs surgery for appropriately selected patients. Biofrontera has guided toward a commercial launch of the new indication in the first quarter of 2027, giving the company time to prepare its sales infrastructure and lamp inventory. The company had also reported Revenue growth in recent quarters even before this approval, suggesting the base actinic keratosis Business was already gaining traction heading into this expanded label.

Why the Stock Reaction May Still Be Complicated

Despite the approval, Biofrontera's financial situation adds real complexity to the bullish narrative. The company has disclosed going-concern language in recent regulatory filings, meaning its auditors have flagged doubt about its ability to fund operations without additional capital, a serious consideration for any small-cap biopharmaceutical name. Separately, an unresolved International Trade Commission dispute concerning imports of the BF-RhodoLED lamp series, the device required to activate Ameluz during treatment, has previously forced the company to revise its outlook and could constrain how quickly it can supply the lamps needed to support a new indication launch. Approval solves one major uncertainty, but it does not by itself resolve the financing and supply-chain questions still facing the company.

Where Things Stand

The FDA's official decision date for Biofrontera's Ameluz PDT application was September 28, 2026, but the agency actually delivered its answer on September 14, approving the therapy for superficial basal cell carcinoma two weeks ahead of schedule based on trial data showing a 65.5% clearance rate against 4.8% for placebo. Whether that approval sends BFRI shares meaningfully higher from here depends less on the regulatory outcome, which is now known, and more on execution: resolving going-concern financing questions, managing the BF-RhodoLED Import dispute, and successfully launching commercially in the first quarter of 2027.